Last reviewed · How we verify
dexamethason
At a glance
| Generic name | dexamethason |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Isa-VRD in TIE HRMM (PHASE4)
- Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers (PHASE2)
- Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection (NA)
- Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (PHASE2)
- REST - Replacing Steroids in the Transplant Ineligble (PHASE2)
- Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery (PHASE4)
- Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response (PHASE4)
- Efficacy and Duration of Pain Relief in Transforaminal and Lumbar Sympathetic Blocks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexamethason CI brief — competitive landscape report
- dexamethason updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI